Discover undervalued stocks with Eulerpool.

Subscribe for $2

Seagen Stock SGEN

Price

0
Today +/-
-0
Today %
-0 %

Seagen stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Seagen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Seagen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Seagen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Seagen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Seagen Stock Price History

DateSeagen Price
12/22/20230 undefined
12/22/2023228.74 undefined
12/21/2023228.74 undefined

Seagen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Seagen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Seagen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Seagen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Seagen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Seagen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Seagen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Seagen’s growth potential.

Seagen Revenue, EBIT and net profit per share

DateSeagen RevenueSeagen EBITSeagen Net Income
2030e8.99 B undefined0 undefined2.45 B undefined
2029e8.27 B undefined2.59 B undefined2.17 B undefined
2028e7.18 B undefined2 B undefined1.65 B undefined
2027e6.32 B undefined1.45 B undefined1.25 B undefined
2026e5.33 B undefined784.71 M undefined695.98 M undefined
2025e4.28 B undefined115.42 M undefined114.92 M undefined
2024e3.32 B undefined-426.67 M undefined-371.43 M undefined
2023e2.51 B undefined-838.38 M undefined-784.66 M undefined
20221.96 B undefined-613 M undefined-610.3 M undefined
20211.57 B undefined-682.1 M undefined-674.5 M undefined
20202.18 B undefined596.9 M undefined613.7 M undefined
2019916.7 M undefined-220.5 M undefined-158.7 M undefined
2018654.7 M undefined-251.5 M undefined-222.7 M undefined
2017482.3 M undefined-195.8 M undefined-125.5 M undefined
2016418.1 M undefined-142.7 M undefined-140.1 M undefined
2015336.8 M undefined-121 M undefined-120.5 M undefined
2014286.8 M undefined-77.4 M undefined-76.1 M undefined
2013269.3 M undefined-62.9 M undefined-62.5 M undefined
2012210.8 M undefined-57.3 M undefined-53.8 M undefined
201194.8 M undefined-144.4 M undefined-152 M undefined
2010107.5 M undefined-68.2 M undefined-66.3 M undefined
200952 M undefined-84.9 M undefined-81.7 M undefined
200835.2 M undefined-91.8 M undefined-85.5 M undefined
200722.4 M undefined-55.6 M undefined-48.9 M undefined
200610 M undefined-40.2 M undefined-36 M undefined
20059.8 M undefined-32.1 M undefined-29.4 M undefined
20046.7 M undefined-37.7 M undefined-72 M undefined
20035.1 M undefined-23.3 M undefined-22.3 M undefined

Seagen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e2030e
000000.010.010.010.010.020.040.050.110.090.210.270.290.340.420.480.650.922.181.571.962.513.324.285.336.327.188.278.99
-----400.0020.0050.0011.11120.0059.0948.57105.77-12.15123.4028.106.3217.4824.4015.3135.6840.06137.45-27.6324.6527.6832.4628.9024.6018.5613.6115.178.78
-155,200.00--155,200.0031,040.0025,866.6717,244.4415,520.007,054.554,434.29100.00100.0096.8193.8192.1989.8688.9989.7188.8086.5495.2089.9880.1879.1061.9646.7836.2929.1224.5621.6218.7717.26
000000000000.050.110.090.20.250.260.30.380.430.570.871.961.261.5500000000
-0-0-0.01-0.02-0.02-0.02-0.07-0.03-0.04-0.05-0.09-0.08-0.07-0.15-0.05-0.06-0.08-0.12-0.14-0.13-0.22-0.160.61-0.67-0.61-0.78-0.370.110.71.251.652.172.45
--300.00150.0015.00-4.35227.27-59.7224.1433.3377.08-4.71-18.52130.30-65.1316.9822.5857.8916.67-10.7177.60-28.83-487.97-209.95-9.5028.52-52.68-130.73509.6580.1431.9531.3613.09
2.22.73.32430.130.74042.248.761.378.791101.1113.1117.9121.6123.4129.2140.7143.2157.7165.5182.3182184.700000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Seagen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Seagen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (B)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                 
00.030.020.040.030.040.040.040.080.110.10.260.280.330.360.370.310.650.590.410.410.812.562.161.74
0000.10.40.81.50.70.968.280.119.35533.429.539.252.961.984.8146.3236325389.3501.9
000.30.70.30.70.80.70.50.71.91.40.80.60.90000000000
00000000000009.537.727.143.55768.16053.285.9116.1200.7427.2
00.10.80.50.30.30.50.31.41.25.56.32.23.84.56.411.911.515.619.143.443.761.8119.2138.3
00.030.030.040.030.040.040.040.090.120.110.350.30.40.440.440.410.770.730.580.651.183.062.872.8
0.30.40.96.46.25.59.58.57.810.31112.312.319.724.840.846.149.662.9103.8103.8220.7258.2268294.9
003.413.418.833.869.737.34.518.965.526.913000063.130049.257.3100.800
0000000000000000000000000
00000000000000003.12.31.50.8300300283.7260.6237.5
00000000000000000000274.7274.7274.7274.7274.7
000.200000000.50.50.565.85.91.89.19.4196.4122176.621.247.264.9
0000.020.030.040.080.050.010.030.080.040.030.030.030.050.050.120.10.30.851.030.940.850.87
0.010.030.030.060.050.080.120.090.10.150.190.390.330.430.470.480.460.90.840.881.52.2143.723.67
                                                 
6.93737.5000000.10.10.10.10.10.10.10.10.10.10.10.10.20.20.20.20.2
000.010.10.110.150.220.220.270.280.390.60.620.830.890.961.021.611.71.812.63.364.364.614.95
-2.1-4.9-12.8-33.5-56.6-78.7-114.1-143.6-179.6-228.5-314-395.7-462-614-667.8-730.3-806.4-926.9-1,067-1,192.6-1,324.6-1,483.2-869.6-1,544-2,154.3
-0.5-0.7-10.1-4.1-1.7-1-0.1-0.200.1-1.4-1.2-1.40000-0.7-0.163.800.20.61.23.5
0000000000000000000000000
0.010.030.030.060.050.070.10.080.090.050.080.210.160.220.230.230.210.690.630.681.271.883.493.072.8
00.10.10.92.21.74.851.32.73.32.95.315.712.959.317.220.82927.444.252.378.1114.8207.9
00.10.7100004.17.812.616.620.537.443.3060.467.291.7105.3147.3207.1279.9454610.6
0000.11.32.14.96.13.218.924.3852938.144.439.948.246.227.834.533.6030.100
0000000000000000000000000
0000000000000000000000000
00.20.823.53.89.711.18.629.440.2104.554.891.2100.699.2125.8134.2148.5167.2225.1259.4388.1568.8818.5
0000000000000000000000000
0000000000000000000000000
0000.32.33.35.63.50.965.268.577.6113.6115.2144.7154.5122.274.955.833.34.370.2124.785.652.3
0000.32.33.35.63.50.965.268.577.6113.6115.2144.7154.5122.274.955.833.34.370.2124.785.652.3
00.20.82.35.87.115.314.69.594.6108.7182.1168.4206.4245.3253.7248209.1204.3200.5229.4329.6512.8654.4870.8
0.010.030.030.060.050.080.120.090.10.150.190.390.330.430.470.480.460.90.840.881.52.2143.723.67
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Seagen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Seagen's financial health and stability.

Assets

Seagen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Seagen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Seagen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Seagen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-2-2-7-20-23-22-35-29-36-48-85-81-66-152-53-62-76-120-140-125-222-158613-674-610
0000111222333468121418242623526669
00000000000000000000-230-200
00004070-6796051-102920-36-71-31-14-53-11242-88-150
00353231415232832545364808510860149211296370458
0000000000000000000000000
0000000000000000000000000
-1-2-4-14-14-17-23-25-3539-62-616-12410-1-60-133-97-118-203-163856-499-453
000-5-10-5-1-1-4-4-4-3-11-10-22-17-13-27-28-21-70-82-52-77
00-25-278-30-4025-104-67-147-112-79-2436-37568129-592-277-1,419288228
00-25-2110-30-3427-98-62-142-813-69-253-36296158-571-207-1,336341305
0000000000000000000000000
0000000000000000000000000
6270476486314361011967188353516554354171363784677125
6272476496314361011967188353516554354171363784677125
0020000000000000000000000
0000000000000000000000000
425-2750001-250-28-12266-339-745652-82196283-133-101
-2.1-2.1-5.2-19.6-15.8-18.3-29-26.9-36.935.5-67.5-66.43.3-135.30.4-23.3-77.2-146.6-124.8-147.6-224.7-234.5774.2-551.3-531.1
0000000000000000000000000

Seagen stock margins

The Seagen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Seagen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Seagen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Seagen's sales revenue. A higher gross margin percentage indicates that the Seagen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Seagen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Seagen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Seagen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Seagen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Seagen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Seagen Margin History

Seagen Gross marginSeagen Profit marginSeagen EBIT marginSeagen Profit margin
2030e79.11 %0 %27.3 %
2029e79.11 %31.38 %26.25 %
2028e79.11 %27.86 %23.03 %
2027e79.11 %22.97 %19.82 %
2026e79.11 %14.73 %13.06 %
2025e79.11 %2.7 %2.69 %
2024e79.11 %-12.86 %-11.19 %
2023e79.11 %-33.47 %-31.32 %
202279.11 %-31.24 %-31.1 %
202180.21 %-43.32 %-42.84 %
202089.99 %27.44 %28.21 %
201995.21 %-24.05 %-17.31 %
201886.51 %-38.41 %-34.02 %
201788.76 %-40.6 %-26.02 %
201689.88 %-34.13 %-33.51 %
201588.9 %-35.93 %-35.78 %
201489.85 %-26.99 %-26.53 %
201392.13 %-23.36 %-23.21 %
201293.6 %-27.18 %-25.52 %
201196.73 %-152.32 %-160.34 %
2010100 %-63.44 %-61.67 %
2009100 %-163.27 %-157.12 %
200879.11 %-260.8 %-242.9 %
200779.11 %-248.21 %-218.3 %
200679.11 %-402 %-360 %
200579.11 %-327.55 %-300 %
200479.11 %-562.69 %-1,074.63 %
200379.11 %-456.86 %-437.25 %

Seagen Stock Sales Revenue, EBIT, Earnings per Share

The Seagen earnings per share therefore indicates how much revenue Seagen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Seagen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Seagen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Seagen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Seagen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Seagen Revenue, EBIT and net profit per share

DateSeagen Sales per ShareSeagen EBIT per shareSeagen Earnings per Share
2030e48.69 undefined0 undefined13.29 undefined
2029e44.76 undefined0 undefined11.75 undefined
2028e38.86 undefined0 undefined8.95 undefined
2027e34.21 undefined0 undefined6.78 undefined
2026e28.85 undefined0 undefined3.77 undefined
2025e23.16 undefined0 undefined0.62 undefined
2024e17.96 undefined0 undefined-2.01 undefined
2023e13.56 undefined0 undefined-4.25 undefined
202210.62 undefined-3.32 undefined-3.3 undefined
20218.65 undefined-3.75 undefined-3.71 undefined
202011.93 undefined3.27 undefined3.37 undefined
20195.54 undefined-1.33 undefined-0.96 undefined
20184.15 undefined-1.59 undefined-1.41 undefined
20173.37 undefined-1.37 undefined-0.88 undefined
20162.97 undefined-1.01 undefined-1 undefined
20152.61 undefined-0.94 undefined-0.93 undefined
20142.32 undefined-0.63 undefined-0.62 undefined
20132.21 undefined-0.52 undefined-0.51 undefined
20121.79 undefined-0.49 undefined-0.46 undefined
20110.84 undefined-1.28 undefined-1.34 undefined
20101.06 undefined-0.67 undefined-0.66 undefined
20090.57 undefined-0.93 undefined-0.9 undefined
20080.45 undefined-1.17 undefined-1.09 undefined
20070.37 undefined-0.91 undefined-0.8 undefined
20060.21 undefined-0.83 undefined-0.74 undefined
20050.23 undefined-0.76 undefined-0.7 undefined
20040.17 undefined-0.94 undefined-1.8 undefined
20030.17 undefined-0.76 undefined-0.73 undefined

Seagen business model

Seagen Inc is a pharmaceutical and biotech company specialized in the development of drugs for cancer treatment and supporting the health of patients with chronic diseases. The company was founded in 1997 and has its headquarters in Bothell, Washington. Seagen Inc's history began when the founders, Clay Siegall and H. Perry Fell, decided to establish a company focused on developing innovative technologies and biological solutions for fighting cancer. The company started with a small workforce and a focus on the development of antibodies against cancer cells. Over the years, Seagen has become a major player in the industry and has launched several successful drugs worldwide. Seagen Inc specializes in the development of cancer medications, including antibodies against cancer cells. The company strives to improve the effectiveness of cancer treatments and reduce the number of side effects. Its flagship products are Adcetris and Padcev, both used for the treatment of specific types of cancer. Adcetris (Brentuximab Vedotin) is an antibody-drug conjugate and the first of its kind approved worldwide for use against Hodgkin lymphomas and systemic anaplastic large cell lymphoma. It contains a special chemical that is bound to an antibody to directly attack cancer cells. Adcetris has proven to be very effective against lymphomas and is available on prescription in many countries. Padcev (Enfortumab Vedotin-ejfv) is another antibody-drug conjugate used for the treatment of bladder cancer. The drug has shown effectiveness in clinical studies and has been approved by the FDA to help patients who have no other treatment options. Padcev is being developed and marketed by Seagen in collaboration with Astellas Pharma. In addition to developing cancer medications, Seagen Inc is also involved in the research and development of technologies for autoimmune disease therapy. The company has developed a technology platform that has proven to be highly effective in the development of antibody-based therapies. This platform is used both internally and in partnerships with other pharmaceutical companies. Seagen Inc also leverages partnerships to expand its business globally and advance the development of new therapies. The company has entered into a strategic partnership with Takeda Pharmaceutical to support the development and commercialization of Adcetris. Additionally, Seagen Inc collaborates with various universities and research institutions to develop new technologies and treatment options. Overall, Seagen Inc has experienced strong growth in recent years and has become a major player in the biotech and pharmaceutical industry. The company remains committed to its mission of developing innovative technologies and solutions for fighting cancer and other chronic diseases. Seagen is one of the most popular companies on Eulerpool.com.

Seagen SWOT Analysis

Strengths

Seagen Inc has established itself as a leader in the biotechnology industry due to its robust research and development capabilities. The company invests heavily in innovation and continuously brings new and improved products to the market.

Seagen Inc's portfolio includes several market-leading medicines that have achieved significant success in treating various diseases. These medicines enjoy strong brand recognition and contribute to the company's overall market position.

Weaknesses

Seagen Inc heavily relies on a limited range of products for generating revenue. This dependence exposes the company to risks associated with changes in market demand or any setbacks in the development of its pipeline.

Seagen Inc has formed strategic partnership agreements with other pharmaceutical companies to collaborate on the development and commercialization of certain products. However, reliance on these partnerships might introduce uncertainties and potential conflicts with partners.

Opportunities

The biotechnology industry is experiencing significant growth, driven by advancements in medical technology and the rising demand for innovative treatments. Seagen Inc can seize this opportunity by expanding its product portfolio to reach new patient populations.

Seagen Inc can explore untapped markets, especially in emerging economies, where there is a growing demand for effective healthcare solutions. Entering these markets can lead to increased revenue and enhanced global presence.

Threats

The biotechnology industry presents intense competition, with numerous established players and new entrants vying for market share. Seagen Inc needs to continuously innovate and differentiate itself to stay ahead in such a competitive landscape.

Due to the highly regulated nature of the pharmaceutical industry, Seagen Inc faces challenges in complying with various regulations and obtaining necessary approvals. Changes in regulations or non-compliance can significantly impact the company's operations and profitability.

Seagen Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Seagen Revenue by Segment

Segmente20222021202020192018
Net product sales1.71 B USD1.39 B USD---
Product--1 B USD627.98 M USD476.9 M USD
Collaboration and License Agreement--1.05 B USD150.25 M USD-
Royalty revenues164.55 M USD150.52 M USD---
Royalty--126.76 M USD138.49 M USD-1.63 M USD
Collaboration and license agreement revenues91.34 M USD38.28 M USD---
License and Service----10.28 M USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Seagen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Seagen historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Seagen shares outstanding

The number of shares was Seagen in 2024 — This indicates how many shares 184.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Seagen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Seagen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Seagen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Seagen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Seagen.

Seagen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.81 -1.15  (-42.41 %)2023 Q3
6/30/2023-0.82 -1.13  (-37.4 %)2023 Q2
3/31/2023-0.84 -0.93  (-11.24 %)2023 Q1
12/31/2022-1.06 -0.8  (24.39 %)2022 Q4
9/30/2022-0.98 -1.03  (-5.59 %)2022 Q3
6/30/2022-0.87 -0.73  (16.47 %)2022 Q2
3/31/2022-1.01 -0.74  (26.96 %)2022 Q1
12/31/2021-0.85 -0.95  (-12.29 %)2021 Q4
9/30/2021-0.59 -1.61  (-174.09 %)2021 Q3
6/30/2021-0.62 -0.47  (24.28 %)2021 Q2
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Seagen stock

Eulerpool World ESG Rating (EESG©)

69/ 100

🌱 Environment

40

👫 Social

99

🏛️ Governance

68

Environment

Scope 1 - Direct Emissions
2,775
Scope 2 - Indirect emissions from purchased energy
392
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
3,167
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees58
Percentage of women in management
Percentage of Asian employees23
Share of Asian management
Percentage of Hispanic/Latino employees4
Hispano/Latino Management share
Percentage of Black employees4
Black Management Share
Percentage of white employees65
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Seagen shareholders

%
Name
Stocks
Change
Date
24.12245 % Baker Bros. Advisors LP44,554,162-4,0886/30/2023
7.17616 % The Vanguard Group, Inc.13,254,362152,1546/30/2023
5.21359 % Pentwater Capital Management LP9,629,5007,874,5006/30/2023
4.91684 % Capital World Investors9,081,409-3,188,0316/30/2023
4.49411 % BlackRock Institutional Trust Company, N.A.8,300,626477,7946/30/2023
3.47440 % Capital International Investors6,417,224-810,6416/30/2023
3.26952 % PRIMECAP Management Company6,038,8081,144,0006/30/2023
1.80520 % State Street Global Advisors (US)3,334,204-20,0286/30/2023
1.73124 % Invesco Capital Management (QQQ Trust)3,197,60819,9419/30/2023
1.22021 % Wellington Management Company, LLP2,253,733-4,575,7306/30/2023
1
2
3
4
5
...
10

Seagen Executives and Management Board

Mr. David Epstein

(61)
Seagen Chief Executive Officer, Director (since 2022)
Compensation 57.46 M

Dr. Roger Dansey

(67)
Seagen President - Research and Development, Chief Medical Officer
Compensation 36.39 M

Dr. Jean Liu

(54)
Seagen Chief Legal Officer, Corporate Secretary
Compensation 5.95 M

Mr. Todd Simpson

(62)
Seagen Chief Financial Officer
Compensation 5.71 M

Mr. Chip Romp

(55)
Seagen Executive Vice President - Commercial U.S.
Compensation 5.03 M
1
2
3

Seagen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
PharmaMar Stock
PharmaMar
SupplierCustomer0,910,710,660,050,270,45
Certara Stock
Certara
SupplierCustomer0,890,84-0,310,600,78
Diversified Healthcare Tr Stock
Diversified Healthcare Tr
SupplierCustomer0,890,920,140,210,440,22
Pieris Pharmaceuticals Stock
Pieris Pharmaceuticals
SupplierCustomer0,790,740,040,520,57-0,04
CytomX Therapeutics Stock
CytomX Therapeutics
SupplierCustomer0,790,93-0,430,590,550,41
Springworks Therapeutics Stock
Springworks Therapeutics
SupplierCustomer0,740,930,300,700,43
Cardinal Health, Inc. Stock
Cardinal Health, Inc.
SupplierCustomer0,740,570,54-0,32-0,42-0,46
City Office REIT, Inc. Stock
City Office REIT, Inc.
SupplierCustomer0,700,89-0,030,290,09-0,43
Astellas Pharma Inc. Stock
Astellas Pharma Inc.
SupplierCustomer0,570,44-0,07-0,30
RemeGen H Stock
RemeGen H
SupplierCustomer0,530,86-0,150,640,61
1
2
3

Most common questions regarding Seagen

What values and corporate philosophy does Seagen represent?

Seagen Inc represents a set of core values and a corporate philosophy that drive its operations. The company places great emphasis on advancing science to develop innovative targeted therapies for patients facing cancer. With a focus on precision medicine, Seagen Inc strives to provide therapies that address significant unmet medical needs. By collaborating with partners, the company aims to advance its mission to make a meaningful difference in the lives of cancer patients. Seagen Inc's dedication to scientific excellence, patient-centricity, and collaboration forms the foundation of its corporate philosophy and guides its pursuit of breakthrough treatments in the field of oncology.

In which countries and regions is Seagen primarily present?

Seagen Inc, a leading biotechnology company, is primarily present in multiple countries and regions across the world. With its headquarters in the United States, Seagen Inc has a significant presence in North America, including the United States and Canada. Additionally, the company extends its operations and reach to various European countries, such as Germany, France, Italy, Spain, and the United Kingdom. Seagen Inc also has a presence in Asia, with a focus on Japan. Through its global presence, Seagen Inc is dedicated to advancing innovative therapies and improving patient outcomes worldwide.

What significant milestones has the company Seagen achieved?

Seagen Inc, a renowned biotechnology company, has achieved numerous significant milestones. Notably, the company received the US Food and Drug Administration (FDA) approval for its groundbreaking antibody-drug conjugate, ADCETRIS®. This therapeutic innovation has revolutionized the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Seagen Inc has also successfully introduced EVOTEC and SGEN-001, expanding its product portfolio and advancing the fight against cancer. The company's commitment to research and development has resulted in crucial advancements and collaborations, consolidating its position as a leader in the biopharmaceutical industry. Seagen Inc's relentless pursuit of innovative solutions continues to make a substantial impact in transforming patients' lives.

What is the history and background of the company Seagen?

Seagen Inc, formerly known as Seattle Genetics, is a biotechnology company based in Bothell, Washington. Established in 1997, Seagen focuses on the development and commercialization of innovative therapies for cancer treatment. The company has been at the forefront of antibody-drug conjugate (ADC) technology, which enables targeted delivery of potent drugs to cancer cells. Seagen's flagship product, ADCETRIS® (brentuximab vedotin), has gained significant recognition as a targeted therapy for Hodgkin lymphoma and certain types of non-Hodgkin lymphoma. With a commitment to advancing breakthrough therapies, Seagen continues to pave the way in the field of oncology.

Who are the main competitors of Seagen in the market?

The main competitors of Seagen Inc in the market include companies such as Genmab, AstraZeneca, and Roche.

In which industries is Seagen primarily active?

Seagen Inc is primarily active in the biotechnology industry.

What is the business model of Seagen?

Seagen Inc, formerly known as Seattle Genetics, operates under a unique business model focused on biotechnology. The company specializes in developing and commercializing innovative antibody-based therapies to treat cancer. By harnessing the power of antibody-drug conjugates (ADCs), Seagen Inc aims to deliver targeted treatments directly to cancer cells while minimizing damage to healthy cells. This approach allows for more effective and precise treatment options, potentially improving patient outcomes. Seagen Inc's commitment to research, development, and collaboration with partners worldwide demonstrates their dedication to advancing cancer care and providing hope for patients globally.

What is the P/E ratio of Seagen 2025?

The P/E ratio cannot be calculated for Seagen at the moment.

What is the P/S ratio of Seagen 2025?

The P/S cannot be calculated for Seagen currently.

What is the Quality Investing of Seagen?

The Quality Investing for Seagen is 6/10.

What is the revenue of Seagen 2025?

The expected Seagen revenue is 4.28 B USD.

How high is the profit of Seagen 2025?

The expected Seagen profit is 114.92 M USD.

What is the business model of Seagen

Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. The company was founded in 1998 and is headquartered in Seattle, USA. Seagen offers a wide range of products and services based on antibodies that can be used for the treatment of cancer and other serious diseases. The company operates in two main divisions: the commercial division and the clinical research and development division. The commercial division of Seagen currently distributes several approved products and therapies, including: - Adcetris: an antibody-drug conjugate (ADC) used for the treatment of lymphoma and Hodgkin's cancer. - Tukysa: an oral medication for the treatment of HER2-positive breast cancer. - Padcev: an ADC used for the treatment of bladder cancer. - Enfortumab Vedotin: an ADC used for the treatment of advanced urothelial carcinoma. - Seattle Genetics: a platform consisting of multiple antibody technologies used for the production of ADCs. Seagen's clinical research division is highly interested in developing new and innovative therapies for cancer and autoimmune diseases. One important area of research is new ADC products and antibody technologies that can help target cancer cells. Seagen pursues a comprehensive business model that includes the sale of new products and therapies, as well as collaborations with various pharmaceutical and biotech companies in the development of new technologies and therapies. The company has also entered into research collaborations with other companies and institutions to accelerate the discovery of new ADCs and other treatment options. In addition, Seagen also offers a range of services in the field of clinical studies, including planning, conducting, and analyzing studies. These services are offered to pharmaceutical and biotech companies developing their own products and technologies. Overall, Seagen aims to further expand its position as a leading provider of antibody-based therapies and products for cancer and autoimmune diseases. The company is committed to offering its customers and partners the best solutions and services to improve the treatment of patients worldwide. Answer: Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. It offers a wide range of products and services for the treatment of cancer and other serious diseases, including antibody-drug conjugates (ADCs) such as Adcetris, Tukysa, Padcev, and Enfortumab Vedotin. Seagen is dedicated to developing new and innovative therapies, particularly in the field of ADC products and antibody technologies. The company operates in both commercial and clinical research divisions and collaborates with other organizations to accelerate the discovery of new treatment options. Additionally, Seagen provides services for clinical studies and aims to be a leading provider of antibody-based therapies worldwide.

What is the Seagen dividend?

Seagen pays a dividend of 0 USD distributed over payouts per year.

How often does Seagen pay dividends?

The dividend cannot currently be calculated for Seagen or the company does not pay out a dividend.

What is the Seagen ISIN?

The ISIN of Seagen is US81181C1045.

What is the Seagen WKN?

The WKN of Seagen is 602322.

What is the Seagen ticker?

The ticker of Seagen is SGEN.

How much dividend does Seagen pay?

Over the past 12 months, Seagen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seagen is expected to pay a dividend of 0 USD.

What is the dividend yield of Seagen?

The current dividend yield of Seagen is .

When does Seagen pay dividends?

Seagen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seagen?

Seagen paid dividends every year for the past 0 years.

What is the dividend of Seagen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seagen located?

Seagen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seagen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seagen from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.

When did Seagen pay the last dividend?

The last dividend was paid out on 9/26/2025.

What was the dividend of Seagen in the year 2024?

In the year 2024, Seagen distributed 0 USD as dividends.

In which currency does Seagen pay out the dividend?

The dividends of Seagen are distributed in USD.

All fundamentals about Seagen

Our stock analysis for Seagen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seagen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.